Join Solentim online at BioProcess International US, 21-25 September 2020

We are delighted to announce that Solentim will join the global bioprocessing community at BioProcess International US (BPI US) on the 21-25 September 2020, an entirely virtual conference and exhibition, as part of Biotech Week Boston.

Mark Stockdale, Amalgamator of Business and Biology at Solentim, will present Building a high confidence image-based clonality workflow. Is 99% clonal assurance good enough?’ at 12:00pm (EST), 22nd September. From limiting dilution, to seeders, pickers and imagers, Mark discusses best practices in this area.

Following the event, his presentation will be available to view here.

Mark Truesdale, CEO, Solentim, commented: “We are excited to virtually attend this event and strengthen our relationships within the global bioprocessing community. Despite the pandemic the past 6 months have been an exciting time for Solentim and we look forward to sharing new insights and data with conference attendees.”

Attendees will benefit from access to over 200 case studies and new data presentations across 6 tracks including cell line development & engineering, cell culture & upstream processing and analytical & quality. In addition, all presentations will be available for 30-days after the event. Following the success of the virtual BPI Europe in July, the conference will connect leading bioprocessing scientists, innovative technologies and vital partners to discuss the latest research in cell line development, cell culture, protein production and CHO cell engineering. Sign up for the opportunity to participate in live Q&As, explore novel bioprocessing technologies in the virtual exhibition hall and engage in networking opportunities.

Please get in touch to find out how Solentim can help you accelerate the development of your Master Cell Banks and ensure you are confidently prepared for regulatory review.

About Mark Stockdale

Mark Stockdale is a keen technology pathfinder and works with Solentim to amalgamate the technical and business functions of the company. Prior to joining Solentim, he worked as a Group Leader at Horizon Discovery Ltd, a scientist for Lonza Biologics, Cyclacel Ltd and started his career at Pfizer. With over 15 years professional experience in cell line development and drug discovery he provides great insight into the future technology requirements in stable cell line development.